{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:12:03Z","timestamp":1778123523824,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04961-8","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:36:49Z","timestamp":1768797409000},"page":"9123-9138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global research trends and future directions for Janus kinase inhibitors in rheumatoid arthritis: a comprehensive bibliometric analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Xiaonan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"2","key":"4961_CR1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD (2018) Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis 77(2):175\u2013187","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4961_CR2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX et al (2024) Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis 83(2):139\u2013160","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4961_CR3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/annrheumdis-2016-210561","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Rigby WF, Van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R et al (2017) Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis 76(7):1279\u20131284","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4961_CR4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR et al (2023) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis 82(1):119\u2013129","journal-title":"Ann Rheum Dis"},{"key":"4961_CR5","doi-asserted-by":"publisher","unstructured":"Davies SC, Hussein IM, Nguyen TM, Parker CE, Khanna R, Jairath V (2020) Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. Cochrane Gut Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2020 Jan 27 [cited 2025 Nov 7];2020(9). Available from: https:\/\/doi.org\/10.1002\/14651858.CD012381.pub2","DOI":"10.1002\/14651858.CD012381.pub2"},{"issue":"3","key":"4961_CR6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaci.2022.03.030","volume":"150","author":"S De Lusignan","year":"2022","unstructured":"De Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C et al (2022) Atopic dermatitis and risk of autoimmune conditions: population-based cohort study. J Allergy Clin Immunol 150(3):709\u2013713","journal-title":"J Allergy Clin Immunol"},{"issue":"10349","key":"4961_CR7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH et al (2022) Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400(10349):369\u2013379","journal-title":"Lancet"},{"issue":"1","key":"4961_CR8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","volume":"61","author":"RJ Desai","year":"2021","unstructured":"Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC (2021) Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatol (Oxford) 61(1):121\u2013130","journal-title":"Rheumatol (Oxford)"},{"issue":"10093","key":"4961_CR9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468","journal-title":"Lancet"},{"issue":"11","key":"4961_CR10","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C et al (2019a) Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 78(11):1454\u20131462","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4961_CR11","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C et al (2019b) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71(11):1788\u20131800","journal-title":"Arthritis Rheumatol"},{"key":"4961_CR12","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","volume":"24","author":"JE Gottenberg","year":"2019","unstructured":"Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M et al (2019) Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ 24:l67","journal-title":"BMJ"},{"issue":"33","key":"4961_CR15","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.3748\/wjg.v23.i33.6137","volume":"23","author":"ML Halling","year":"2017","unstructured":"Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK (2017) Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. WJG 23(33):6137\u201346","journal-title":"WJG"},{"issue":"1","key":"4961_CR16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W (2021) The JAK\/STAT signaling pathway: from bench to clinic. Sig Transduct Target Ther 6(1):402","journal-title":"Sig Transduct Target Ther"},{"issue":"10271","key":"4961_CR17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F et al (2021) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397(10271):305\u2013317","journal-title":"Lancet"},{"issue":"6","key":"4961_CR18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ (2022) Tofacitinib and risk of cardiovascular outcomes: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. Ann Rheum Dis 81(6):798\u2013804","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4961_CR19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ard.2025.01.023","volume":"84","author":"V Konzett","year":"2025","unstructured":"Konzett V, Smolen JS, Nash P, Aletaha D, Winthrop K, D\u00f6rner T et al (2025) Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement. Ann Rheum Dis 84(5):680\u2013696","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4961_CR20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41588-020-00763-1","volume":"53","author":"A Kurilshikov","year":"2021","unstructured":"Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A et al (2021) Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet 53(2):156\u2013165","journal-title":"Nat Genet"},{"issue":"5","key":"4961_CR21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02533-2020","volume":"57","author":"S Matson","year":"2021","unstructured":"Matson S, Lee J, Eickelberg O (2021) Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 57(5):2002533","journal-title":"Eur Respir J"},{"issue":"2","key":"4961_CR22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","volume":"82","author":"V Molander","year":"2023","unstructured":"Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J et al (2023) Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis 82(2):189\u2013197","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4961_CR23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002409","volume":"8","author":"M Mortezavi","year":"2022","unstructured":"Mortezavi M, Martin DA, Schulze-Koops H (2022) After 25 years of drug development, do we know JAK? RMD Open 8(2):e002409","journal-title":"RMD Open"},{"issue":"5","key":"4961_CR24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","volume":"84","author":"P Nash","year":"2025","unstructured":"Nash P, Kerschbaumer A, Konzett V, Aletaha D, D\u00f6rner T, Fleischmann R et al (2025) Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update. Ann Rheum Dis 84(5):664\u2013679","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4961_CR25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrd1441","volume":"3","author":"JJ O\u2019Shea","year":"2004","unstructured":"O\u2019Shea JJ, Pesu M, Borie DC, Changelian PS (2004) A new modality for immunosuppression: targeting the JAK\/STAT pathway. Nat Rev Drug Discov 3(7):555\u2013564","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"4961_CR26","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L (2020) Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 158(6):1554-1573.e12","journal-title":"Gastroenterology"},{"issue":"6","key":"4961_CR27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"F Rivellese","year":"2022","unstructured":"Rivellese F, Surace AEA, Goldmann K, Sciacca E, \u00c7ubuk C, Giorli G et al (2022) Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med 28(6):1256\u20131268","journal-title":"Nat Med"},{"issue":"16","key":"4961_CR28","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N et al (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 383(16):1511\u20131521","journal-title":"N Engl J Med"},{"issue":"3","key":"4961_CR29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","volume":"17","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, D\u2019Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N et al (2023) Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme. J Crohns Colitis. 17(3):338\u201351","journal-title":"J Crohns Colitis."},{"issue":"11","key":"4961_CR30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard-2023-224479","volume":"82","author":"A Saviano","year":"2023","unstructured":"Saviano A, Manosour AA, Raucci F, Merlino F, Marigliano N, Schettino A et al (2023) New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A\/F function. Ann Rheum Dis 82(11):1415\u20131428","journal-title":"Ann Rheum Dis"},{"key":"4961_CR31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102400","volume":"110","author":"HU Scherer","year":"2020","unstructured":"Scherer HU, H\u00e4upl T, Burmester GR (2020) The etiology of rheumatoid arthritis. J Autoimmun 110:102400","journal-title":"J Autoimmun"},{"issue":"12","key":"4961_CR32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ (2017) Jak inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16(12):843\u2013862","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"4961_CR33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMe2117663","volume":"386","author":"JA Singh","year":"2022","unstructured":"Singh JA (2022) Risks and benefits of Janus kinase inhibitors in rheumatoid arthritis - Past, Present, and Future. N Engl J Med 386(4):387\u2013389","journal-title":"N Engl J Med"},{"issue":"10188","key":"4961_CR34","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-monotherapy): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393(10188):2303\u20132311","journal-title":"Lancet"},{"issue":"6","key":"4961_CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4961_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4961_CR37","doi-asserted-by":"crossref","first-page":"e805","DOI":"10.1016\/S2665-9913(24)00132-2","volume":"6","author":"K Song","year":"2024","unstructured":"Song K, Satsangi J, Coates LC (2024) Arthritis complicating inflammatory bowel disease\u2014 the future is now. Lancet Rheumatol 6(11):e805\u2013e810","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"4961_CR38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE et al (2024) Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol 20(2):101\u2013115","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"4961_CR39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/ard-2024-226350","volume":"84","author":"H Tamai","year":"2025","unstructured":"Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K et al (2025) Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial. Ann Rheum Dis 84(1):41\u201348","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4961_CR40","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H et al (2022) Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis 81(11):1515\u20131523","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4961_CR41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","volume":"18","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Cohen SB (2022) Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol 18(5):301\u2013304","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"4961_CR42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC et al (2022) Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis 81(2):184\u2013192","journal-title":"Ann Rheum Dis"},{"key":"4961_CR43","volume":"13","author":"D Wu","year":"2022","unstructured":"Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G et al (2022) Systemic complications of rheumatoid arthritis: focus on pathogenesis and treatment. Front Immunol 13:1051082","journal-title":"Front Immunol"},{"issue":"4","key":"4961_CR44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"issue":"1","key":"4961_CR45","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02149-2021","volume":"60","author":"N Zhao","year":"2022","unstructured":"Zhao N, Al-Aly Z, Zheng B, Van Donkelaar A, Martin RV, Pineau CA et al (2022a) Fine particulate matter components and interstitial lung disease in rheumatoid arthritis. Eur Respir J 60(1):2102149","journal-title":"Eur Respir J"},{"key":"4961_CR46","volume":"150","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Hua Z, Luo X, Li Y, Yu L, Li M et al (2022b) Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother 150:113074","journal-title":"Biomed Pharmacother"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04961-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04961-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04961-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:40:56Z","timestamp":1778121656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04961-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4961"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04961-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}